



PRESS RELEASE
Grenoble, December 17, 2014

Eveon announces the signing of an agreement with the pharmaceutical group Advanced Accelerator Applications for a medical injection device in oncology.

EVEON's objective is to develop and produce an innovative automated injection system for the treatment of solid tumours.

GRENOBLE, France – December 17, 2014 - EVEON, designer and manufacturer of medical devices for the preparation and administration of medicinal products, has announced the signing of an agreement with Advanced Accelerator Applications (AAA), a European leader in the production and marketing of radiopharmaceutical products for PET (Positron emission tomography).

AAA is a major name in personalised and nuclear medicine. The group is committed to the development of new therapeutic product candidates.

Along with other partners, AAA is currently working on a strategic industrial innovation project called "TheraneaM –Therapy by neutron activation using Microparticles" that aims to develop a technology of innovative micro-curietherapy for the treatment of solid tumours.

As part of this project backed by BPIFrance, AAA is developing a new treatment technique that requires a precise injector. Eveon has taken on the development and delivery of this injector for clinical phases, as well as beyond for marketing phases.

In this context, AAA sought to enlist the skills and expertise of EVEON in order to entrust them with the development and future production of an automated system for the intratumoral administration of radioactive microparticles for the treatment of solid tumours.

"We are proud to have signed this agreement with a European leader in molecular nuclear medicine," explained Vincent Tempelaere, EVEON's CEO. "This agreement reinforces EVEON's position as a major name in oncology. Cancer treatment is experiencing a revolution thanks to new surgical practices, but also thanks to the arrival of new targeted treatments. EVEON plans to play a major role in this transition by providing a simple and

precise technology for administering these treatments, for the benefit of healthcare professional and also for that of patients."

For the first 2 indications targeted as part of this project, brain metastases and pancreatic cancer, nearly 100,000 patients would be eligible for this new therapy.

"We are glad to be collaborating with EVEON. Their technology is extremely interesting, and in it, we see real potential for molecular nuclear therapy," added Stefano Buono, CEO of AAA.

For more information about EVEON: *Head office at 345 rue Lavoisier-38330 Montbonnot Saint-Martin. www.eveon.eu*

*The Eveon group develops innovative medical devices that address the needs of patients, doctors and nurses, whether in **preventative medicine**, by improving disease detection or in **curative medicine**, by automating treatment preparation, facilitating treatment administration and by connecting patients with medical staff. ISO 13487 certified, and with 18 families of patents, the Eveon Group has clients on 4 continents in more than 20 countries and has received several awards, including the Young Innovative Enterprise Trophy awarded by the magazine Usine Nouvelle in the Innovative Products category and the 1st prize of the international competition "Inventer Demain" (Invent Tomorrow) in December 2014.*

Contact: Vincent Tempelaere – +33 (0)4.76.41.43.92 - vte@eveon.eu